Publications
(2023)
De novo design of transmembrane β barrels.. Science. 10.1126/science.abc8182
(2021) De novo designed proteins neutralize lethal snake venom toxins. Nature. 10.1038/s41586-024-08393-x
(2025) Decoupling peptide binding from T cell receptor recognition with engineered chimeric MHC-I molecules. Front Immunol. 14, 1116906
(2023) Depletion of creatine phosphagen energetics with a covalent creatine kinase inhibitor. Nat Chem Biol. 10.1038/s41589-023-01273-x
(2023) Design of an equilibrative nucleoside transporter subtype 1 inhibitor for pain relief. Nat Commun. 15, 10738
(2024) Design of an equilibrative nucleoside transporter subtype 1 inhibitor for pain relief. Nat Commun. 15, 10738
(2024) Design of an equilibrative nucleoside transporter subtype 1 inhibitor for pain relief. Nat Commun. 15, 10738
(2024) (2023) A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas. Cancer Cell. 29, 90-103
(2016) (2010) Development of 2nd generation aminomethyl spectinomycins that overcome native efflux in abscessus. Proc Natl Acad Sci U S A. 121, e2314101120
(2024) Development of a covalent inhibitor of gut bacterial bile salt hydrolases. Nat Chem Biol. 16, 318-326
(2020) Development of a universal nanobody-binding Fab module for fiducial-assisted cryo-EM studies of membrane proteins. Proc Natl Acad Sci U S A. 10.1073/pnas.2115435118
(2021) Development of First-in-Class Dual Sirt2/HDAC6 Inhibitors as Molecular Tools for Dual Inhibition of Tubulin Deacetylation. J Med Chem. 66, 14787-14814
(2023) Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid. ChemMedChem. 16, 2982-3002
(2021) Development of novel molecular probes of the Rio1 atypical protein kinase. Biochim Biophys Acta. 1834, 1292-301
(2013) Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat Commun. 13, 1891
(2022) Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat Commun. 13, 1891
(2022) Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat Commun. 13, 1891
(2022) (2015) (2015) Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening. Nat Commun. 16, 152
(2025) Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells. J Exp Clin Cancer Res. 40, 317
(2021) Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells. J Exp Clin Cancer Res. 40, 317
(2021)